Evidence map›Paper›PMID 40693450›Full record

ReviewPharmaceutical patent analyst2024

Bispecific anti-CD38/CD28 antibodies for treatment of multiple myeloma.

Martin Perez-Santos, Maricruz Anaya-Ruiz, Donaciano Flores-Robles, Alejandro Millán-Vega, Pavel Sierra-Martínez

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Pharmaceutical patent analyst, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Martin Perez-SantosInnovation and Knowledge Transfer Department, Benemerita Autonomous University of Puebla, Puebla, México.
Maricruz Anaya-RuizLaboratorio de Biologia Celular, Centro de Investigacion Biomedica de Oriente, Instituto Mexicano del Seguro Social, Puebla, Mexico.
Donaciano Flores-RoblesCentro de Investigaciones Microbiológicas, Universidad Autónoma de Guerrero, Chilpancingo, México.
Alejandro Millán-VegaCentro de Investigaciones Microbiológicas, Universidad Autónoma de Guerrero, Chilpancingo, México.
Pavel Sierra-MartínezCentro de Investigaciones Microbiológicas, Universidad Autónoma de Guerrero, Chilpancingo, México.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionSince CD38 is a protein expressed at high levels in multiple myeloma cells, it is an ideal target for antibody design for treatment. AREAS COVERED: Patent US11905332, which describes two anti-CD38/CD28 bispecific antibodies (bsAb6031 and bsAb7945) with the potential for the treatment of multiple myeloma, was evaluated. The results described in the patent show that the anti-CD38/CD28 bispecific antibodies caused elevated EXPERT OPINION: Anti-CD38/CD28 bispecific antibodies have the potential to be used alone or in combination with other antibodies, including anti-BCMA/CD3 antibodies, for the treatment of multiple myeloma.

Indexed as

ADP-ribosyl Cyclase 1Antibodies, BispecificCD28 AntigensMultiple MyelomaAnimalsHumansMicePatents as TopicADP-ribosyl Cyclase 1Antibodies, BispecificCD28 Antigensbispecific antibodyCD28CD38multiple myelomapatent

Identifiers

PMID40693450
PMCPMC12367085

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.